The melatonin- N,N-dibenzyl(N-methyl)amine hybrid ITH91/IQM157 affords neuroprotection in an in vitro Alzheimer's model via hemo-oxygenase-1 induction

ACS Chemical Neuroscience

Volumn 6, Issue 2, 2015, Pages 288-296

  Buendia, Izaskun ^a,b   Egea, Javier ^a,b   Parada, Esther ^a,b   Navarro, Elisa ^a,b   León, Rafael ^a,b   Rodríguez Franco, María Isabel ^c   López, Manuela G ^a,b  

^a INSTITUTO TEÓFILO HERNANDO   (Spain)

^b UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^c INSTITUTO DE QUÍMICA MÉDICA   (Spain)

Author keywords

acetylcholinestaerase inhibitor; Alzheimer's disease; beta amyloid; ITH91 IQM157; melatonin; neuroprotection; okadaic acid; SH SY5Y

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; AMYLOID BETA PROTEIN; CHELERYTHRINE; CHOLINESTERASE INHIBITOR; DONEPEZIL; FREE RADICAL; HEME OXYGENASE 1; ITH 91 PLUS IQM 157; MECAMYLAMINE; MELATONIN; MELATONIN DERIVATIVE; METHYLAMINE; MITOGEN ACTIVATED PROTEIN KINASE; NEUROPROTECTIVE AGENT; NICOTINIC RECEPTOR; OKADAIC ACID; PROTEIN AGGREGATE; TAU PROTEIN; UNCLASSIFIED DRUG; HMOX1 PROTEIN, HUMAN; MAPT PROTEIN, HUMAN; MELATONIN RECEPTOR; PROTEIN KINASE B; PROTEIN KINASE C;

ALZHEIMER DISEASE; APOPTOSIS; ARTICLE; BLOOD BRAIN BARRIER; CELL DEATH; CELL SURVIVAL; CELL VIABILITY; CHOLINESTERASE INHIBITION; CYTOARCHITECTURE; CYTOTOXICITY; ENZYME INDUCTION; HUMAN; HUMAN CELL; IN VITRO STUDY; NERVE CELL; NERVE DEGENERATION; NEUROBLASTOMA CELL LINE; NEUROPROTECTION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; CYTOSKELETON; DRUG EFFECTS; ENZYMOLOGY; METABOLISM; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY; TUMOR CELL LINE;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; CELL DEATH; CELL LINE, TUMOR; CHOLINESTERASE INHIBITORS; CYTOSKELETON; HEME OXYGENASE-1; HUMANS; MAP KINASE SIGNALING SYSTEM; MELATONIN; METHYLAMINES; NEUROPROTECTIVE AGENTS; OKADAIC ACID; PHOSPHORYLATION; PROTEIN AGGREGATES; PROTEIN KINASE C; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, MELATONIN; RECEPTORS, NICOTINIC; TAU PROTEINS;

EID: 84923220443     PISSN: None     EISSN: 19487193     Source Type: Journal    
DOI: 10.1021/cn5002073     Document Type: Article

References (47)

1. Leon, R., Garcia, A. G., and Marco-Contelles, J. (2013) Recent advances in the multitarget-directed ligands approach for the treatment of Alzheimer's disease Med. Res. Rev. 33, 139-189
2. Hardy, J. (2002) Testing times for the "amyloid cascade hypothesis" Neurobiol. Aging 23, 1073-1074
3. Avila, J. (2000) Tau aggregation into fibrillar polymers: taupathies FEBS Lett. 476, 89-92
4. Bloom, G. S. (2014) Amyloid-β and Tau: The Trigger and Bullet in Alzheimer Disease Pathogenesis JAMA Neurol. 10.1001/jamaneurol.2013.5847
5. Schneider, L. S., Dagerman, K. S., Higgins, J. P., and McShane, R. (2011) Lack of evidence for the efficacy of memantine in mild Alzheimer disease Arch. Neurol. 68, 991-998
6. Tan, D. X., Reiter, R. J., Manchester, L. C., Yan, M. T., El-Sawi, M., Sainz, R. M., Mayo, J. C., Kohen, R., Allegra, M., and Hardeland, R. (2002) Chemical and physical properties and potential mechanisms: melatonin as a broad spectrum antioxidant and free radical scavenger Curr. Top. Med. Chem. 2, 181-197
7. Liu, R. Y., Zhou, J. N., van Heerikhuize, J., Hofman, M. A., and Swaab, D. F. (1999) Decreased melatonin levels in postmortem cerebrospinal fluid in relation to aging, Alzheimer's disease, and apolipoprotein E-epsilon4/4 genotype J. Clin. Endocrinol. Metab. 84, 323-327
8. Pandi-Perumal, S. R., BaHammam, A. S., Brown, G. M., Spence, D. W., Bharti, V. K., Kaur, C., Hardeland, R., and Cardinali, D. P. (2013) Melatonin antioxidative defense: Therapeutical implications for aging and neurodegenerative processes Neurotoxic. Res. 23, 267-300
9. Wu, Y. H., Feenstra, M. G., Zhou, J. N., Liu, R. Y., Torano, J. S., Van Kan, H. J., Fischer, D. F., Ravid, R., and Swaab, D. F. (2003) Molecular changes underlying reduced pineal melatonin levels in Alzheimer disease: Alterations in preclinical and clinical stages J. Clin. Endocrinol. Metab. 88, 5898-5906
10. De Butte, M. and Pappas, B. A. (2007) Pinealectomy causes hippocampal CA1 and CA3 cell loss: reversal by melatonin supplementation Neurobiol. Aging 28, 306-313
11. Rosales-Corral, S. A., Lopez-Armas, G., Cruz-Ramos, J., Melnikov, V. G., Tan, D. X., Manchester, L. C., Munoz, R., and Reiter, R. J. (2012) Alterations in Lipid Levels of Mitochondrial Membranes Induced by Amyloid-beta: A Protective Role of Melatonin Int. J. Alzheimer's Dis 2012, 459806
12. Jun, Z., Li, Z., Fang, W., Fengzhen, Y., Puyuan, W., Wenwen, L., Zhi, S., and Bondy, S. C. (2013) Melatonin decreases levels of S100beta and NFKappaB, increases levels of synaptophysin in a rat model of Alzheimer's disease Curr. Aging Sci. 6, 142-149
13. Polimeni, G., Esposito, E., Bevelacqua, V., Guarneri, C., and Cuzzocrea, S. (2014) Role of melatonin supplementation in neurodegenerative disorders Front. Biosci., Landmark Ed. 19, 429-446
14. He, H., Dong, W., and Huang, F. (2010) Anti-amyloidogenic and anti-apoptotic role of melatonin in Alzheimer disease Curr. Neuropharmacol. 8, 211-217
15. Asayama, K., Yamadera, H., Ito, T., Suzuki, H., Kudo, Y., and Endo, S. (2003) Double blind study of melatonin effects on the sleep-wake rhythm, cognitive and non-cognitive functions in Alzheimer type dementia J. Nippon Med. Sch. 70, 334-341
16. Rosales-Corral, S. A., Acuna-Castroviejo, D., Coto-Montes, A., Boga, J. A., Manchester, L. C., Fuentes-Broto, L., Korkmaz, A., Ma, S., Tan, D. X., and Reiter, R. J. (2012) Alzheimer's disease: pathological mechanisms and the beneficial role of melatonin J. Pineal Res. 52, 167-202
17. Romero, A., Egea, J., Garcia, A. G., and Lopez, M. G. (2010) Synergistic neuroprotective effect of combined low concentrations of galantamine and melatonin against oxidative stress in SH-SY5Y neuroblastoma cells J. Pineal Res. 49, 141-148
18. López-Iglesias, B., Pérez, C., Morales-García, J. A., Alonso-Gil, S., Pérez-Castillo, A., Romero, A., López, M. G., Villarroya, M., Conde, S., and Rodríguez-Franco, M. I. (2014) New melatonin- N, N -dibenzyl(N -methyl)amine hybrids: Potent neurogenic agents with antioxidant, cholinergic, and neuroprotective properties as innovative drugs for Alzheimer's disease J. Med. Chem. 57, 3773-3785
19. Rapoport, S. I. (2002) Hydrogen magnetic resonance spectroscopy in Alzheimer's disease Lancet Neurol. 1, 82
20. Roberson, E. D., Scearce-Levie, K., Palop, J. J., Yan, F., Cheng, I. H., Wu, T., Gerstein, H., Yu, G. Q., and Mucke, L. (2007) Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model Science 316, 750-754
21. Ribe, E. M., Perez, M., Puig, B., Gich, I., Lim, F., Cuadrado, M., Sesma, T., Catena, S., Sanchez, B., Nieto, M., Gomez-Ramos, P., Moran, M. A., Cabodevilla, F., Samaranch, L., Ortiz, L., Perez, A., Ferrer, I., Avila, J., and Gomez-Isla, T. (2005) Accelerated amyloid deposition, neurofibrillary degeneration and neuronal loss in double mutant APP/tau transgenic mice Neurobiol Dis 20, 814-822
22. Oddo, S., Caccamo, A., Kitazawa, M., Tseng, B. P., and LaFerla, F. M. (2003) Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer's disease Neurobiol. Aging 24, 1063-1070
23. Del Barrio, L., Martin-de-Saavedra, M. D., Romero, A., Parada, E., Egea, J., Avila, J., McIntosh, J. M., Wonnacott, S., and Lopez, M. G. (2011) Neurotoxicity induced by okadaic acid in the human neuroblastoma SH-SY5Y line can be differentially prevented by alpha7 and beta2∗ nicotinic stimulation Toxicol. Sci. 123, 193-205
24. Rhein, V., Song, X., Wiesner, A., Ittner, L. M., Baysang, G., Meier, F., Ozmen, L., Bluethmann, H., Drose, S., Brandt, U., Savaskan, E., Czech, C., Gotz, J., and Eckert, A. (2009) Amyloid-beta and tau synergistically impair the oxidative phosphorylation system in triple transgenic Alzheimer's disease mice Proc. Natl. Acad. Sci. U. S. A. 106, 20057-20062
25. Arias, E., Gallego-Sandin, S., Villarroya, M., Garcia, A. G., and Lopez, M. G. (2005) Unequal neuroprotection afforded by the acetylcholinesterase inhibitors galantamine, donepezil, and rivastigmine in SH-SY5Y neuroblastoma cells: role of nicotinic receptors J. Pharmacol. Exp. Ther. 315, 1346-1353
26. Shen, H., Kihara, T., Hongo, H., Wu, X., Kem, W. R., Shimohama, S., Akaike, A., Niidome, T., and Sugimoto, H. (2010) Neuroprotection by donepezil against glutamate excitotoxicity involves stimulation of alpha7 nicotinic receptors and internalization of NMDA receptors Br. J. Pharmacol. 161, 127-139
27. Hamouda, A. K., Kimm, T., and Cohen, J. B. (2013) Physostigmine and galanthamine bind in the presence of agonist at the canonical and noncanonical subunit interfaces of a nicotinic acetylcholine receptor J. Neurosci. 33, 485-494
28. Ni, R., Marutle, A., and Nordberg, A. (2013) Modulation of alpha7 nicotinic acetylcholine receptor and fibrillar amyloid-beta interactions in Alzheimer's disease brain J. Alzheimer's Dis. 33, 841-851
29. Masilamoni, J. G., Jesudason, E. P., Dhandayuthapani, S., Ashok, B. S., Vignesh, S., Jebaraj, W. C., Paul, S. F., and Jayakumar, R. (2008) The neuroprotective role of melatonin against amyloid beta peptide injected mice Free Radical Res. 42, 661-673
30. Pappolla, M. A., Chyan, Y. J., Poeggeler, B., Bozner, P., Ghiso, J., LeDoux, S. P., and Wilson, G. L. (1999) Alzheimer beta protein mediated oxidative damage of mitochondrial DNA: Prevention by melatonin J. Pineal Res. 27, 226-229
31. Lahiri, D. K. (1999) Melatonin affects the metabolism of the beta-amyloid precursor protein in different cell types J. Pineal Res. 26, 137-146
32. Dragicevic, N., Copes, N., O'Neal-Moffitt, G., Jin, J., Buzzeo, R., Mamcarz, M., Tan, J., Cao, C., Olcese, J. M., Arendash, G. W., and Bradshaw, P. C. (2011) Melatonin treatment restores mitochondrial function in Alzheimer's mice: a mitochondrial protective role of melatonin membrane receptor signaling J. Pineal Res. 51, 75-86
33. Poeggeler, B., Miravalle, L., Zagorski, M. G., Wisniewski, T., Chyan, Y. J., Zhang, Y., Shao, H., Bryant-Thomas, T., Vidal, R., Frangione, B., Ghiso, J., and Pappolla, M. A. (2001) Melatonin reverses the profibrillogenic activity of apolipoprotein E4 on the Alzheimer amyloid Abeta peptide Biochemistry 40, 14995-15001
34. Inestrosa, N. C., Alvarez, A., and Calderon, F. (1996) Acetylcholinesterase is a senile plaque component that promotes assembly of amyloid beta-peptide into Alzheimer's filaments Mol. Psychiatry 1, 359-361
35. Phiel, C. J., Wilson, C. A., Lee, V. M., and Klein, P. S. (2003) GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides Nature 423, 435-439
36. Cacabelos, R. (2002) Pharmacogenomics in Alzheimer's disease Mini-Rev. Med. Chem. 2, 59-84
37. Parada, E., Buendia, I., Leon, R., Negredo, P., Romero, A., Cuadrado, A., Lopez, M. G., and Egea, J. (2013) Neuroprotective effect of melatonin against ischemia is partially mediated by alpha-7 nicotinic receptor modulation and HO-1 overexpression J. Pineal Res. 56, 204-212
38. Kawamata, J. and Shimohama, S. (2011) Stimulating nicotinic receptors trigger multiple pathways attenuating cytotoxicity in models of Alzheimer's and Parkinson's diseases J. Alzheimer's Dis 24 (Suppl 2) 95-109
39. Stambolic, V. and Woodgett, J. R. (1994) Mitogen inactivation of glycogen synthase kinase-3 beta in intact cells via serine 9 phosphorylation Biochem. J. 303 (Pt 3) 701-704
40. Cuchillo-Ibanez, I., Balmaceda, V., Botella-Lopez, A., Rabano, A., Avila, J., and Saez-Valero, J. (2013) Beta-amyloid impairs reelin signaling PLoS One 8, e72297
41. Ramser, E. M., Gan, K. J., Decker, H., Fan, E. Y., Suzuki, M. M., Ferreira, S. T., and Silverman, M. A. (2013) Amyloid-beta oligomers induce tau-independent disruption of BDNF axonal transport via calcineurin activation in cultured hippocampal neurons Mol. Biol. Cell 24, 2494-2505
42. Salazar, M., Rojo, A. I., Velasco, D., de Sagarra, R. M., and Cuadrado, A. (2006) Glycogen synthase kinase-3beta inhibits the xenobiotic and antioxidant cell response by direct phosphorylation and nuclear exclusion of the transcription factor Nrf2 J. Biol. Chem. 281, 14841-14851
43. Chen, J. (2014) Heme oxygenase in neuroprotection: From mechanisms to therapeutic implications Rev. Neurosci. 25, 269-280
44. Jazwa, A. and Cuadrado, A. (2010) Targeting heme oxygenase-1 for neuroprotection and neuroinflammation in neurodegenerative diseases Curr. Drug Targets 11, 1517-1531
45. Parada, E., Egea, J., Buendia, I., Negredo, P., Cunha, A. C., Cardoso, S., Soares, M. P., and Lopez, M. G. (2013) The microglial alpha7-acetylcholine nicotinic receptor is a key element in promoting neuroprotection by inducing heme oxygenase-1 via nuclear factor erythroid-2-related factor 2 Antioxid. Redox Signaling 19, 1135-1148
46. Nakao, A., Kaczorowski, D. J., Zuckerbraun, B. S., Lei, J., Faleo, G., Deguchi, K., McCurry, K. R., Billiar, T. R., and Kanno, S. (2008) Galantamine and carbon monoxide protect brain microvascular endothelial cells by heme oxygenase-1 induction Biochem. Biophys. Res. Commun. 367, 674-679
47. Denizot, F. and Lang, R. (1986) Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability J. Immunol. Methods 89, 271-277